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Background: In France, the rapid scale-up of buprenorphine, an opioid maintenance treatment (OMT), in primary
care for drug users has led to an impressive reduction in HIV prevalence among injecting drug users (IDU) but has
had no major effect on Hepatitis C incidence. To date, patients willing to start methadone can only do so in a
methadone clinic (a medical centre for drug and alcohol dependence (CSAPA) or a hospital setting) and are
referred to primary care physicians after dose stabilization. This study aims to assess the effectiveness of methadone
in patients who initiated treatment in primary care compared with those who initiated it in a CSAPA, by measuring
abstinence from street opioid use after one year of treatment.
Methods/Design: The ANRS-Methaville study is a randomized multicenter non-inferiority control trial comparing
methadone induction (lasting approximately 2 weeks) in primary care and in CSAPA. The model of care chosen for
methadone induction in primary care was based on study-specific pre-training of all physicians, exclusion criteria
and daily supervision of methadone during the initiation phase. Between January 2009 and January 2011, 10 sites
each having one CSAPA and several primary care physicians, were identified to recruit patients to be randomized
into two groups, one starting methadone in primary care (n = 147), the other in CSAPA (n = 48). The primary
outcome of the study is the proportion of participants abstinent from street opioids after 1 year of treatment i.e.
non-inferiority of primary care model in terms of the proportion of patients not using street opioids compared with
the proportion observed in those starting methadone in a CSAPA.
Discussion: The ANRS-Methaville study is the first in France to use an interventional trial to improve access to OMT
for drug users. Once the non-inferiority results become available, the Ministry of Health and agency for the safety of
health products may change the the New Drug Application (NDA) of methadone and make methadone induction
by trained primary care physicians possible.
The trial is registered with the French Agency of Pharmaceutical Products (AFSSAPS) under the number 2008-
A0277-48, the European Union Drug Regulating Authorities Clinical Trials.
Number Eudract 2008-001338-28, the ClinicalTrials.gov Identifier: NCT00657397 and the International Standard
Randomised Controlled Trial Number Register ISRCTN31125511.
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Since 1996, two opioid maintenance treatments (OMT)
have been marketed in France for opioid dependence:
methadone and buprenorphine. It is acknowledged that
recommended doses of buprenorphine are less effective
than methadone in retaining patients in treatment [1].
Currently, methadone and buprenorphine are accessible
through different models of delivery and consequently
target different drug-user populations [2]. Buprenor-
phine is prescribed mainly in primary care, whereas
methadone can only be initiated in a methadone clinic
(medical centre for drug and alcohol dependence
(CSAPA) or in a hospital setting), where patients receive
both comprehensive general care and care for psychiatric
comorbidities. In addition, in France, a patient can start
buprenorphine promptly (even after the first visit) in pri-
mary care, whereas methadone induction in a CSAPA
can take between 2 and 4 weeks. This is due to the fact
that in general the patient must often first complete a
psychiatric evaluation and psychosocial and motivational
assessments.
Despite the lack of official clinical guidelines about the
specific drug(s) to be prescribed in first-line treatment,
buprenorphine is prescribed more often and is more
widely available in France through primary care. This is
due to its safety profile. While the effectiveness of the
two treatments at adequate doses (for buprenorphine,
this means doses which are higher than those recom-
mended) is comparable, the risk of overdose is lower in
buprenorphine patients [1]. As a consequence, bupre-
norphine is more accessible to individuals who are less
severely opioid dependent [3]. Although this model of
care for opioid dependence has had a positive impact on
HIV epidemics and overdoses in drug users in France, it
is still inadequate in terms of reducing the spread of Hepa-
titis C epidemics (HCV) [4]. Indeed, the persistence of
risky behaviours among opioid-dependent drug users could
be interpreted as a response to an inadequate model of
care. Many do not have access to methadone because of a
limited access to CSAPA. In addition, it has been shown
that a proportion of buprenorphine patients, albeit mar-
ginal, administers the treatment by a non-indicated route,
either intranasally [5] or intravenously [6]. Expanded access
to methadone treatment for opioid dependent individuals
through innovative models of care is a major challenge for
the control of HIV and HCV infection. The study
described here is based primarily on the identification of a
possible model for methadone initiation in primary care.
Although the long-term effectiveness of methadone induc-
tion in specialized centres on different outcomes, including
opioid use, has already been proven [7,8], it is expensive,
access is inadequate and many patients perceive it as stig-
matizing. For these reasons, we conducted a trial to assess
the non-inferiority of the proportion of patients abstinentfrom street opioid in patients inducted in primary care ver-
sus those inducted in CSAPA after one year of methadone
treatment.
Methods/Design
Pre-trial phase
The study was designed in response to a request by the
French Ministry of Health which asked the AIDS agency
(ANRS) to develop an experimental study which would
evaluate the effectiveness of methadone in primary care.
The research unit responsible for conducting the study
is the unit U912 of the National Institute of Health and
Medical Research (INSERM) in Marseilles, under the
scientific responsibility of Patrizia Carrieri.
Before designing the trial, a multidisciplinary working
group which also included members of patients’ associa-
tions was set up by the ANRS.
One of the major points to decide upon was the iden-
tification of a model for primary care which could
maximize access while minimizing the risk of overdose.
This model was designed from previous experiences of
methadone provision in primary care [9] and particularly
the Scottish experience [10]. The main points retained
were: 1) study-specific pre-training for primary care phy-
sicians; 2) a shared care model, based on the patient-
primary care physicians-CSAPA-pharmacist network; 3)
the exclusion of patients with triple codependence on
opioids/benzodiazepines/alcohol, as screened by MINI;
4) the daily supervision at the local pharmacy during the
initiation phase for patients starting methadone in pri-
mary care; 5) patient accountability for treatment intake
and appropriate storage.
Several subgroups were charged with, respectively,
preparing the guidelines for methadone prescription, up-
dating the methadone drug-drug interactions manual
and designing an information booklet for the patient.
Participants
From January 2009 to January 2010, we recruited 195
men and women in 10 cities (Avignon, Bayonne, Besancon,
Bordeaux, Boulogne, Le Havre, Marseille, Metz, Rouen,
Strasbourg) who were all over 18 and less than 70 years
old, opioid-dependent in accordance with the DSM-IV cri-
teria, and with an indication for methadone treatment
(patients seeking care for opioid dependence and metha-
done prescription naive for at least one month or patients
receiving buprenorphine but needing to switch to metha-
done treatment for medical reasons). The only difference
between this trial and some previous trials [11,12] was that
in our study patients who had triple dependence (opioids,
benzodiazepines and alcohol) and those who could not be
contacted by phone were excluded. The reason for exclud-
ing opioid-dependent individuals also presenting with
benzodiazepine and alcohol dependence was based on the
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risk of overdose associated with benzodiazepine use and
alcohol use [13].
Research design
This study is a multi-site, open-label, randomized con-
trolled non-inferiority trial, comparing methadone induc-
tion in France in a CSAPA or with primary care physicians
with an allocation ratio of 1 :2. The randomization proced-
ure allocated patients to the two different types of pre-
scriber for methadone induction, lasting approximately 14
days for both prescribers).
A pilot phase was first carried out at one site (Avignon
CSAPA and local primary care physicians) at a “slowed”
recruitment rate in order to identify and prevent pos-
sible future problems when the trial was extended to the
other sites.
Physician recruitment and training
A one-day training session was provided to all physicians
involved in the study to standardize how to initiate
methadone treatment (as set down by the trial’s guidelines)
and to become acquainted with the design of the trial. This
training session also provided the opportunity to collect
data about the physicians’ own socio-demographic charac-
teristics and their history of care with opioid-dependent
individuals.
We trained 57 prescribers and each site was character-
ized by a group of trained primary care physicians and a
group of trained physicians from a CSAPA. Primary care
and CSAPA physicians collaborated closely together to
make the randomization process possible and to ensure ef-
fective patient follow-up. Concerning patient selection, the
Mini-International Neuropsychiatric Interview (MINI) was
used to ascertain DSM-IV diagnosis [14] of substance
disorders in order to exclude patients with alcohol-
benzodiazepines co-dependence. It has been already shown
that such patients require closer follow-up [15] and are at
greater risk of overdose [13]. During pre-trial training, phy-
sicians learned how to use the MINI and familiarized
themselves with the trial’s guidelines, including details on
the protocol. They also received a manual on drug-drug
interactions [16]. One of the main goals of the training ses-
sion was to remind physicians about the pharmacokinetic
profile of methadone during induction i.e. its slow and pro-
gressive plasma scale-up before reaching a steady-state. For
example the trainer commented that: “An excessive dose
given on Monday may lead to an overdose only on Thurs-
day”. The session also helped physicians to identify patients
with a high risk of overdose. Furthermore, it emphasized
the importance of the information physicians needed to
provide patients when initiating methadone. A trial-
specific information booklet designed for the patient was
drafted explaining the study protocol, all the risks andbenefits of initiating methadone, how to deal with compli-
cated or unexpected issues such as travel and holidays,
effects on one’s desire to become pregnant, as well as infor-
mation on intoxication, overdoses (e.g. how to recognize
overdose symptoms) and other side effects.
Pharmacist involvement
We also enrolled primary care pharmacists who agreed
to deliver methadone and supervise dose taking during
the 2-week induction phase (except during weekends, in
most cases) for all the trial’s participants. Pharmacists
were asked to complete a self-administered question-
naire before and after the trial and also to register all
stock entries and exits for methadone doses.
Remuneration
Physicians who accepted to participate in the trial were
remunerated for the one-day initial training session and
for each medical visit during the induction phase. Parti-
cipants were covered for all health costs related to their
methadone induction.
Intervention
Patient screening
The first visit took place when a patient willing to be
treated for his/her opioid dependence came to a Metha-
ville physician, either in primary care or in a CSAPA
(see Figure 1). During this visit, the physician explained
the study protocol to the patient and performed the trial
screening to confirm the patient’s eligibility. If he/she
was eligible to enter the study and provided written
informed consent to participate, the physician then im-
mediately called the centre of methodology and manage-
ment (CMM) of unit U912 to randomize the patient
into one of the two groups. Details were exchanged and
at the end of the medical visit the participant knew
where he/she had to initiate methadone: in primary care
or in a CSAPA.
This study was approved by the Ethics Committee of
Persons Protection in Paris, France.
The screening physician, whether in a CSAPA or in a
primary care setting, provided the randomization setting
to the patient: if the patient was randomized into the
same type of setting at that where initial screening took
place, he/she could initiate methadone where he/she was
screened. Otherwise he/she had to go to the other type
of setting.
Methadone initiation
During the induction period, the selected physician for
the methadone induction had to adjust the methadone
dose until stabilization was reached. This induction
period was crucial and required a great deal of attention
by both the physician and the patient in order to reach a
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symptoms’ alleviation. The initial methadone prescrip-
tion could not be above 40 mg a day. After writing this
first prescription, the physician was required to call the
local pharmacist where the patient had chosen to take
the methadone. The patient was then given the pre-
scribed dose (in syrup form) at the pharmacy and had a
medical visit 2 or 4 hours after that intake in order to
assess the tolerance of the first prescribed dose. During
the induction period, the patient had to see the phys-
ician at least twice a week after the initial prescription
consultation. Depending on the severity of opioid de-
pendence, the first dose prescribed could increase by
10 mg every 2 to 4 days with a medical visit 48 hours
after each dose increase.Maintenance phase
After the initial 14 days, the participant could choose to
remain in the allocated prescription setting or to change
to the other one (i.e. to primary care or CSAPA).
The possible risks for participants were methadone
side effects, which are the same as those encountered in
standard clinical care: drowsiness, sweating, constipa-
tion, sleeping and libido disorder [17]. The potential
benefit for patients initiating in primary care was that
they would have the chance to initiate methadone in pri-
mary care, something not currently possible in the
standard system of care.
As there is an increased risk of overdose until
stabilization of doses is reached, special guidelines for
methadone prescription were drawn up and used, both
to train physicians and to have standardized guidelines
throughout the course of the trial.Lost to follow-up
During the induction phase (from day 0 to day 14), the
patient had to:
(1) regularly go to the pharmacy (according to the
scheduled date of prescription refill) during opening
hours to take the treatment. If he/she didn’t appear
there for more than 48 hours, the pharmacist had
to inform the centre of methodology and
management (CMM) which in turn contacted the
participant.
(2) see the physician for the scheduled medical visit,
every 72 hours on average. If this appointment was
not observed, the physician had to call the CMM.
If after 24 hours of investigation, the CMM still could
not find the participant in either of these two cases, he/
she was considered as “lost to follow-up”. The CMM
had to then contact the centre of evaluation and infor-
mation on drug dependence (CEIP) to check that the
participant had not had an overdose.Safety
An independent data and safety monitoring board peri-
odically reviewed the trial’s efficacy and safety data.
This safety committee comprised several experts in
the field including addiction psychiatrists, forensic
scientists, pharmacologists, methodologists and institu-
tional scientists.
Stopping rules were based on occurrence of overdoses
and severe adverse effects.
Objectives
The trial is nearing completion. Its primary objective is
to demonstrate the non-inferiority of the proportion of
individuals abstinent from street opioids after one year
of methadone in patients inducted in primary care with
those inducted in CSAPA. Patients who initiated metha-
done in primary care are expected to have better out-
comes compared with those in CSAPA in terms of
retention, quality of life and satisfaction after 1 year of
methadone treatment.
Outcomes and instruments
Multiple sources were used for data collection at screen-
ing (week preceding recruitment and first/seventh day
after recruitment), at recruitment (day zero or month
zero), induction (from the first to the second week of
treatment) and maintenance (third, sixth and twelfth
months). Data collection methods (ongoing) include
face-to-face interviews, phone interviews using a Com-
puter Assisted Telephone Interview [18] and self-
administered questionnaires, all adapted and validated
for the type of information to be gathered.
The Opiate Treatment Index (OTI), a multi-dimensional
questionnaire based on patients’ self-report [19] is being
used to measure Methaville’s primary outcome. This con-
sists in measuring the proportion of all participants absti-
nent from street opioids after 1 year of treatment. Some
secondary outcomes are also measured. First, retention in
treatment and occurrence of overdoses are assessed. The
prevalence of other HCV risk transmission practices is also
documented using a series of questions extracted from a
standardized questionnaire specifically adapted for this
purpose - the Blood-Borne Virus Transmission Risk As-
sessment (BBV-TRAQ) [20,21] - and also the question-
naire used by Lucidarme et al. in their longitudinal study
[22,23]. Other data about indicators relevant for the pur-
pose of this study have been collected: depressive symp-
toms (using the CES-D questionnaire [24]), suicidal risk
(the Beck Hopelessness Scale [25]), impulsivity (the Barratt
Impulsiveness Scale), sensation seeking (the Brief Sensa-
tion Seeking Scale (BSSS) [26]), tobacco dependence (the
Fagerstrom test [27]), alcohol consumption (the AUDIT
questionnaire [28]), pain assessment (the Brief Pain Inven-
tory [29]), adherence to methadone prescription, patient-
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(the subjective opioid withdrawal symptoms scale (SOWS)
[31]), quality of life (the 12-item Short-Form Health Sur-
vey (SF-12) [32]), Attention Deficit Hyperactivity Disorder
(Adult ADHD Self-Report Scale 6 item version [33]), urin-
ary drug screening, and finally socio-demographic infor-
mation on history of incarceration and contact with
associations. Quality assurance and data security measures
were established and approved for this protocol on the
21st of May 2008.
Sample size
We used the proportion of all patients abstinent from
street opioids after 1-year of methadone treatment for
the sample size. Many studies have shown that 60% to
80% of opioid-dependent individuals treated with metha-
done completely stopped using street opioids after one
year of treatment [34-36]. The hypothesis for this study
was that after one year of methadone treatment, the pro-
portion of patients not using opioids in CSAPA would
be 70%. Considering a margin of inferiority of 15% in
the primary care arm, 200 patients needed to be
recruited to investigate non-inferiority.
Randomization
For allocation of the participants to a primary care or a
CSAPA physician, a computer-generated list of random
numbers was used within a secured centralized internet
system. Randomization sequencing was not stratified by the
CMM, which generated the randomization sequence by
computer and provided the number by phone to the pre-
scribing physicians when recruiting a patient into the study.
Blinding
By definition, the arm could not be masked from the
prescribing physician but it was masked from all the sci-
entific team involved in the trial. It was obviously
unmasked to the logistics team who conducted the inter-
views and to statisticians and the data managers of the
research group, because they had to regularly meet and
submit reports to the Independent Committee of the
trial. The study will be unmasked at the end of the last
M12 interview, during the course of 2012.
Statistical methods
The trial was initially designed as a non-inferiority trial
aimed to show the non-inferiority of the proportion of
non-injectors who started methadone in primary care
compared to those who started it in a CSAPA. However,
as the number of patients injecting opioids at recruit-
ment was low, the primary outcome was changed as ‘the
proportion of patients abstinent from of street opioids
after 1 year’, and the dimension of the study was re-com-
puted. These changes were approved by the ScientificCommittee of the trial, the Independent Committee and
the Ethical Committee (CPP).
Secondary outcomes are the occurrence of fatal and
non-fatal overdoses and the percentage of retention in
both arms. We also investigated the prevalence of other
HCV transmission practices and the effectiveness of
treatment in terms of adherence, social insertion, addict-
ive behaviours, quality of life, psychiatric comorbidities,
social insertion, reduction in criminal acts and cost
effectiveness.
When data analysis is completed later in 2012, the
computation of the 95% confidence interval for the pro-
portion of patients abstinent from street opioids at M12
in the two arms will be based on Intention To Treat
(ITT), with lost to follow-up considered as a therapeutic
failure (opioid users). Additional analyses will be per-
formed without ITT, focusing on the most recent avail-
able information about opioid use during treatment.
Mixed generalized linear models analyses will be used to
identify predictors of the different outcomes. Non-
inclusion or non-termination biases will be controlled
for using selection models - including Heckman type
models [37] - and other approaches to take into account
for the drop out process [38].
Discussion
To date, the ANRS-Methaville study is the first in
France to be requested by a governmental agency with
the objective of potentially changing the existing legal
framework of an opioid maintenance treatment (OMT).
We hope that methadone will be initiated by trained pri-
mary care physicians and in turn, that it will contribute
to providing improved access to methadone in France.
However, the risk of overdose occurring during the in-
duction phase of treatment [39] highlights the require-
ment for closer follow-up early on, together with the
systematic training of volunteer physicians. For many
years now, in the United Kingdom, methadone has been
mostly prescribed in primary care (as opposed to special
centres) [9]. This system of access to methadone has
shown its effectiveness but also the risks associated with
widespread access [40,41]. In Scotland, methadone dose
supervision in community pharmacies is currently in
place [10,42].
This is why the present trial is based not only on
guidelines for methadone prescription and provision in
primary care but also on a shared-care model.
Primary care physicians should work within a drug de-
pendence care network and/or specialized centre, such
as a CSAPA, and have documented experience of care
for drug users. In addition, pharmacists must have direct
contact with the methadone prescribing physician and
must be involved from the beginning of the trial in order
to guarantee effective supervision and follow-up of
Opioid dependent individual
Screening on eligibility 
or being in treatment failure with buprenorphine)
Inclusion criteria : Exclusion criteria :
-over 18 and under 70 years old, - contraindications to methadone treatment,
-opioid dependent (DSM-IV criteria), - triple dependence (opioids, benzodiazepines, alcohol),
-having an indication for  methadone treatment - being a prison inmate 
(being methadone naive from the last 30 days - pregnancy
. - not contactable by phone 
Written informed consent to participate in ANRS-Methaville trial 
Randomization
Primary care physician : Experimental group CSAPA physician : Control group 
2-week initiation phase (either primary care or CSAPA) 
Participant Follow-up choice (either primary care or CSAPA)
Follow-up assessments at Months 3, 6 and 12
Exp patient in 
primary care 
Control patient 
in CSAPA 
Methaville trained physician
Exp patient in 
CSAPA
Control patient in 
primary care
- 
Figure 1 Flowchart for patient inclusion and study design.
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pharmacists more into the health care system for drug
users. Some previous studies have already shown that
pharmacists appear to be in favour of providing OMT,
supervising intake [43] and playing an important role in
treatment delivery, including referring difficult patients
to other services [44]. This potentially enhanced role for
pharmacists is a unique opportunity to develop andimprove the harm reduction network through the train-
ing of pharmacists.
This study may inform the development of any
improved structuring of the existing framework for
OMT induction in primary care through training and
networking between physicians and pharmacists. The
improved treatment efficacy of involving pharmacists as
a key component of prevention for drug users has
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sterile injecting equipment [45].
In this trial, because the recruitment of primary care
physicians had to be carried out in close collaboration
with a drug and alcohol centre, it was impossible to in-
clude primary care physicians in sites without any
CSAPA (especially in rural settings where primary care
physicians are mostly general practitioners). The repre-
sentativeness of the study sample would certainly have
been better if we had been able to include such rural-
based physicians. However, we can hypothesize that
whatever results we find will also be applicable to these
latter as our intervention included pre-training for all
the physicians who initiated methadone treatment.
This trial is a unique opportunity to encourage
increased access to OMT, especially for opioid dependent
individuals who do not have access to methadone for geo-
graphical reasons or for reasons of preference. In
addition, it is an innovative experiment in France using
preventive intervention research in opioid dependent
individuals.
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